News

uniQure hopeful in gene therapy trial
Enlarge image

Gene TherapyNetherlands

uniQure hopeful in gene therapy trial

08.01.2016 - A new hope for gene therapy: Dutch biotech uniQure has presented promising results from its haemophilia B gene therapy clinical trial. A jump in the company’s shares followed the announcement.

In a low-dose cohort of an ongoing Phase I/II clinical trial being conducted in adult hemophilia B patients, uniQures AAV5/FIX gene therapy, AMT-060, has resulted in encouraging data. Topline results showed that four out of the five patients were able to discontinue prophylactic recombinant factor IX. Two patients’ factor IX rose to 5.5% and 4.5% of the normal level, from below 2% before the treatment.

Haemophilia B patients themselves cannot produce enough factor IX, a protein responsible for blood clotting, leading to excessive bleeding. Patients are currently treated by repeated infusion of recombinant factor IX. uniQure’s gene therapy AMT-060 consists of a codon-optimised wild type FIX gene and the LP1 liver promoter together with the AAV5 viral vector, manufactured using uniQure’s insect cell based manufacturing technology. AMT-060 is administered, without immunosuppressant therapy, through the peripheral vein in a one treatment session for approximately 30 minutes.

“These early data from the low-dose cohort suggest that AMT-060 is generally well-tolerated and capable of successfully transducing the liver resulting in clinically meaningful FIX expression levels,” uniQure said in a statement. Frank W.G. Leebeek an investigator in the study at the Erasmus Medical Center in Rotterdam, added: “Thus far, the overall tolerability and FIX expression profile in the low-dose cohort is encouraging for patients with hemophilia B and support  the continuation of the study.”

Shareholders shared the company’s optimism. uniQure’s shares rose from below US$15 on 6th January, to more than US$17 on the 8th.

“Today, we are the only AAV gene therapy company in the world with both proprietary, commercial-scale manufacturing capabilities and encouraging clinical data across multiple diseases,” commented uniQure CEO Dan Soland.

© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2016-01/uniqure-hopeful-in-gene-therapy-trial.html

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

European UnionUKEU

24.06.2016 After the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have. Representatives from biotech industry, research and policits have expressed their concerns and hopes on the upcoming Brexit.

Investment FundUKIrelandEULuxembourg

24.06.2016 UK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period of seven years.

ImmunotherapyFranceEU

22.06.2016 TxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Science’s tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.

Clinical TrialsUK

21.06.2016 Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.

R&DSwitzerlandUK

16.06.2016 With support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.

FinancingEUNetherlands

14.06.2016 European specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.

AwardEUPortugalGermanyDenmarkFrance

09.06.2016 Exceptional inventors from all over Europe have been honoured with the European Inventor Award 2016. With the award, the European Patent Office recognises the achievements of inventors from Denmark, France, Germany, the Netherlands, the UK and the US.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PLETHORA (UK)3.38 GBP12.67%
  • SCANCELL HOLDINGS (UK)16.25 GBP10.17%
  • ALMIRALL (E)12.42 EUR9.33%

FLOP

  • THERAMETRICS (CH)0.03 CHF-25.00%
  • EVOCUTIS (UK)0.04 GBP-20.00%
  • BIONOR PHARMA (N)0.56 NOK-11.11%

TOP

  • THERAMETRICS (CH)0.03 CHF50.0%
  • IMMUPHARMA (UK)33.50 GBP17.5%
  • ABCAM (UK)735.00 GBP16.7%

FLOP

  • SARTORIUS (D)68.49 EUR-71.9%
  • CIRCASSIA LIMITED (L)96.60 GBP-63.7%
  • VALNEVA (F)2.10 EUR-36.7%

TOP

  • KARO BIO (S)26.50 SEK1766.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)12.24 EUR558.1%

FLOP

  • BB BIOTECH (D)40.82 EUR-84.6%
  • EVOCUTIS (UK)0.04 GBP-81.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.40 SEK-78.1%

No liability assumed, Date: 29.06.2016